Publications by authors named "Javier Borja"

Claim this Profile
G
Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study.
Rosa M Antonijoan, Ignasi Gich, Analia Azaro, Sergio Sainz, Joaquim Balanzó, Javier Borja

Eur J Clin Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association".
Javier Borja, Julián García-Rafanell

Stroke· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study.
Marc Miravitlles, Iñaki Izquierdo, Alberto Herrejón, Juan Vicente Torres, Eva Baró, Javier Borja

Respir Med· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
Iñaki Izquierdo, Javier Borja, Sandra Rovira, Pilar Pelagio, Ferran Torres

Arzneimittelforschung· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Antonio Valero, Fernando de la Torre, José Antonio Castillo, Pilar Rivas, Alfonso del Cuvillo, Javier Borja

Drug Saf· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of stroke in patients with ischemic stroke or transient ischemic attack.
Javier Borja, Iñaki Izquierdo, Julián García-Rafanell

Stroke· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic treatment in atrial fibrillation. Response to: Bereznicki LR, Peterson GM, Jackson SL, Jeffrey EC: the risks of warfarin use in the elderly. Expert Opin. Drug Saf. (2006) 5(3):417-431.
Javier Borja, Olga García, Iñaki Izquierdo

Expert Opin Drug Saf· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypertrophic cardiomyopathy. Combination of beta blockers and verapamil may be risky.
Javier Borja, Iñaki Izquierdo, Josep Guindo

BMJ· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies in cardiology.
Javier Borja, Eva Arnáiz, Iñaki Izquierdo, Mario Souto

Lancet· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clopidogrel and metoprolol in myocardial infarction.
Javier Borja, Olga García, Esther Donado, Iñaki Izquierdo

Lancet· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ezetimibe coadministered with fenofibrate: some safety questions.
Javier Borja

Eur Heart J· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral antiplatelet therapy.
Javier Borja

JAMA· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seriousness of adverse events: medical judgment is important.
Javier Borja, Esther Donado, Mario Souto

BMJ· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amoxicillin for non-severe pneumonia in young children: admission to hospital may indicate adverse effects.
Javier Borja, David Rigau

BMJ· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Cholestatic hepatitis due to amoxicillin-clavulanic acid with positive re-exposure: Importance of proper terminology in drug vigilance].
Javier Borja, David Rigau, Mario Souto

Enferm Infecc Microbiol Clin· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Adverse reactions to drugs among hospitalized elderly patients].
Javier Borja, David Rigau, Iñaki Pérez, Mario Souto

Med Clin (Barc)· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clopidogrel and percutaneous coronary interventions.
Javier Borja, Iñaki Pérez, Guillermo De la Cruz

JAMA· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fondaparinux versus enoxaparin for prevention of venous thromboembolism.
Javier Borja, Pere Olivella, Jorge Curto

Lancet· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of low-molecular-weight heparin in the management of acute coronary syndromes.
Javier Borja

Curr Opin Cardiol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enoxaparin after high-risk coronary stenting.
Javier Borja, Jorge Curto, Joaquin Campbell, Marco A Paz

J Am Coll Cardiol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Aldosterone antagonists in the treatment of heart failure].
Josep Guindo, Javier Borja

Med Clin (Barc)· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation.
Javier Borja, Pere Olivella

Thromb Haemost· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis